Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence invited the manufacturer (Galapagos) of filgotinib (Jyseleca(®)), as part of the Single Technology Appraisal process, to submit evidence for the clinical effectiveness and cost effectiveness of filgotinib for treating moderately to severely activ...

Descripción completa

Detalles Bibliográficos
Autores principales: van Asselt, Antoinette D. I., Armstrong, Nigel, Kimman, Merel, Peeters, Andrea, McDermott, Kevin, Stirk, Lisa, Ahmadu, Charlotte, Govers, Tim M., Hoentjen, Frank, Joore, Manuela A., Grimm, Sabine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929013/
https://www.ncbi.nlm.nih.gov/pubmed/36725788
http://dx.doi.org/10.1007/s40273-023-01244-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929013/
https://www.ncbi.nlm.nih.gov/pubmed/36725788
http://dx.doi.org/10.1007/s40273-023-01244-z

Ejemplares similares